Tiziana Life Sciences Ltd (TLSA)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

1.19 on 9 Oct 2026

3 buys0 sales at will0 planned sales

Fiscal year 2024, ended 31 Dec 2024, as filed

Net income

$11.86M

Free cash flow

$1.55M

Return on equity

-301.4%

Return on capital

-317.0%

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
5 Aug 2026	Elrifi Ivor Chief Executive Officer	Bought	$237.62K	5.2%
4 Aug 2026	Elrifi Ivor Chief Executive Officer	Bought	$81.29K	1.9%
3 Aug 2026	Elrifi Ivor Chief Executive Officer	Bought	$667.00K	17.5%

34out of 100

Profitability 0

Financial strength 50

Growth n/a

Insiders 65

Strongest on insiders (65), weakest on profitability (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$985.91K

3 buys, 1 buyer

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan